Abstract
Bovine leukemia virus (BLV) infection of rabbits is a tractable model system to evaluate vaccination strategies against lymphotropic retroviruses, which represent a global human health problem. We have previously developed genetically simplified BLV structural gene vector (SGV) that replicates BLV structural and enzymatic genes independently of BLV regulatory and accessory genes. Results of a 20-month study in a rabbit model demonstrated that BLV SGV induces an antiviral immunological response and lacks pathogenicity. Here, these chronically infected-BLV SGV rabbits are assessed in a proof-of-principle study of preventative vaccination against challenge with pathogenic BLV. This study commences 24 months after BLV SGV inoculation and proceeds for an additional 20 months. The previously characterized BLV SGV rabbits and age-matched control rabbits were challenged with 1 × 10 8 fetal lamb kidney/BLV producer cells. BLV SGV rabbits seroconverted upon BLV challenge, but did not progress to BLV infection nor clinical disease. By contrast, naive rabbits became infected and succumbed to lymphotropic disease. Our findings provide proof-of-principle that chronic infection with BLV SGV induces protection against BLV infection. The data indicate that SGV based on HTLV or HIV is a promising approach against lymphotropic disease by human retroviruses.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 434-439 |
| Number of pages | 6 |
| Journal | Virology |
| Volume | 329 |
| Issue number | 2 |
| DOIs | |
| State | Published - Nov 24 2004 |
| Externally published | Yes |
Fingerprint
Keywords
- Live attenuated vaccine
- Replication-competent retroviral vector
- Rex-independent gene expression
ASJC Scopus subject areas
- Virology
- Infectious Diseases
Cite this
Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits. / Altanerova, Veronika; Holicova, Dana; Kucerova, Lucia; Altaner, Cestmir; Lairmore, Michael Dale; Boris-Lawrie, Kathleen.
In: Virology, Vol. 329, No. 2, 24.11.2004, p. 434-439.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits
AU - Altanerova, Veronika
AU - Holicova, Dana
AU - Kucerova, Lucia
AU - Altaner, Cestmir
AU - Lairmore, Michael Dale
AU - Boris-Lawrie, Kathleen
PY - 2004/11/24
Y1 - 2004/11/24
N2 - Bovine leukemia virus (BLV) infection of rabbits is a tractable model system to evaluate vaccination strategies against lymphotropic retroviruses, which represent a global human health problem. We have previously developed genetically simplified BLV structural gene vector (SGV) that replicates BLV structural and enzymatic genes independently of BLV regulatory and accessory genes. Results of a 20-month study in a rabbit model demonstrated that BLV SGV induces an antiviral immunological response and lacks pathogenicity. Here, these chronically infected-BLV SGV rabbits are assessed in a proof-of-principle study of preventative vaccination against challenge with pathogenic BLV. This study commences 24 months after BLV SGV inoculation and proceeds for an additional 20 months. The previously characterized BLV SGV rabbits and age-matched control rabbits were challenged with 1 × 10 8 fetal lamb kidney/BLV producer cells. BLV SGV rabbits seroconverted upon BLV challenge, but did not progress to BLV infection nor clinical disease. By contrast, naive rabbits became infected and succumbed to lymphotropic disease. Our findings provide proof-of-principle that chronic infection with BLV SGV induces protection against BLV infection. The data indicate that SGV based on HTLV or HIV is a promising approach against lymphotropic disease by human retroviruses.
AB - Bovine leukemia virus (BLV) infection of rabbits is a tractable model system to evaluate vaccination strategies against lymphotropic retroviruses, which represent a global human health problem. We have previously developed genetically simplified BLV structural gene vector (SGV) that replicates BLV structural and enzymatic genes independently of BLV regulatory and accessory genes. Results of a 20-month study in a rabbit model demonstrated that BLV SGV induces an antiviral immunological response and lacks pathogenicity. Here, these chronically infected-BLV SGV rabbits are assessed in a proof-of-principle study of preventative vaccination against challenge with pathogenic BLV. This study commences 24 months after BLV SGV inoculation and proceeds for an additional 20 months. The previously characterized BLV SGV rabbits and age-matched control rabbits were challenged with 1 × 10 8 fetal lamb kidney/BLV producer cells. BLV SGV rabbits seroconverted upon BLV challenge, but did not progress to BLV infection nor clinical disease. By contrast, naive rabbits became infected and succumbed to lymphotropic disease. Our findings provide proof-of-principle that chronic infection with BLV SGV induces protection against BLV infection. The data indicate that SGV based on HTLV or HIV is a promising approach against lymphotropic disease by human retroviruses.
KW - Live attenuated vaccine
KW - Replication-competent retroviral vector
KW - Rex-independent gene expression
UR - http://www.scopus.com/inward/record.url?scp=7044260729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7044260729&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2004.09.001
DO - 10.1016/j.virol.2004.09.001
M3 - Article
C2 - 15518821
AN - SCOPUS:7044260729
VL - 329
SP - 434
EP - 439
JO - Virology
JF - Virology
SN - 0042-6822
IS - 2
ER -